A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours

Trial Profile

A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Belinostat (Primary) ; Carboplatin; Paclitaxel
  • Indications Bladder cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors TopoTarget
  • Most Recent Events

    • 22 Dec 2009 Actual patient number changed from 36 to 80 as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Interim results in 7 patients reported at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' conference, according to a TopoTarget media release.
    • 21 Oct 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top